key: cord-0256527-0f4bdssh
authors: Saito, S.; Chung, C. H. H.; Jacob, A.; Nuradin, N.; Meyer, A. E.; Saito, T.; Yang, H.; Kolls, J. K.; Thannickal, V. J.; Liu, Y.-Z.; Lasky, J. A.
title: Hematopoietic and Lung Platelet Biogenesis as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis (IPF)
date: 2022-04-05
journal: nan
DOI: 10.1101/2022.04.04.22273424
sha: 8ae22fc1b6209b271466398699e2beb2d57307de
doc_id: 256527
cord_uid: 0f4bdssh

Rationale and objectives The role of human lung megakaryocytes in homeostasis and their dynamics in disease states remain unknown. We sought to investigate whether megakaryocyte/platelet gene signatures are altered in IPF. Methods We analyzed publicly available transcriptome datasets of lung tissue, bronchoalveolar lavage (BAL) cells, and peripheral whole blood from IPF patients and healthy controls. Enrichment of megakaryocyte and platelet gene signatures in those datasets were estimated using xCell, a novel computational method. Furthermore, we analyzed whether mean platelet volume (MPV) and platelet counts in peripheral blood are associated with lung transplant-free survival in our IPF cohort. Results In lung tissue, megakaryocyte scores were significantly lower in IPF than in controls. In BAL cells, platelet scores were significantly lower in IPF than in controls, and lower platelet scores were associated with lower lung transplant-free survival in IPF. In contrast, in blood, megakaryocyte scores were significantly higher in IPF than in controls, and higher megakaryocyte scores were associated with lower disease progression-free survival in IPF. Furthermore, higher MPV was associated with lower transplant-free survival in our IPF cohort, independent of age, sex, forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO). Conclusions In IPF, megakaryocyte/platelet gene signatures were altered in a compartment-specific manner. Moreover, those signatures and MPV in blood were associated with important clinical outcomes such as transplant-free survival. These findings provide new insights into altered megakaryocyte/platelet biogenesis in IPF and suggest the potential utility of megakaryocyte/platelet-based biomarkers in IPF.

A recent study in mice indicated that platelet-releasing megakaryocytes reside in the lung interstitium as well as within lung blood vessels, and that the lung is a site of platelet biogenesis (1) . Other studies have also reported that megakaryocytes are present in mouse lungs and that they are immunomodulatory (e.g., antigen presentation to T cells) (2, 3) .

The presence of megakaryocytes in human lungs has also been reported in SARS-CoV-2 infection (4-7); however, the characteristics and role of lung megakaryocytes in homeostatic conditions, as well as disease conditions such as idiopathic pulmonary fibrosis (IPF), are not well understood. We investigated whether megakaryocyte/platelet gene signatures are altered in IPF by analyzing publicly available transcriptome datasets with xCell, a novel computational method.

We found that megakaryocyte/platelet gene signatures in lung, BAL cells, and blood are altered in lower platelet enrichment scores (below the median) using a log-rank test. A p-value <0.05 was considered statistically significant.

For gene signatures for megakaryocytes and platelets in peripheral whole blood transcriptome, we compared the disease progression-free survival (i.e., survival without significant [>10%] decline in FVC over six months) between patients with high megakaryocyte/platelet enrichment scores (above the median) and patients with lower megakaryocyte/platelet enrichment scores (below the median), using a log-rank test. A p-value <0.05 was considered statistically significant.

This study was approved by the Tulane University Institutional Review Board (Study Number: 2020-1146) with a waiver of informed consent, as this was a retrospective examination of clinically indicated data. IPF patients followed at Tulane Medical Center or University Medical Center New

Orleans were enrolled in this study. Patient characteristics are shown in Table 2 .

The diagnosis of IPF was made according to international guidelines (9). We compared the lung transplant-free survival between patients with higher mean platelet volume (MPV) (above the median) and patients with lower MPV (below the median) using a log-rank test. We also compared the survival between patients with higher platelet counts (above the median) and patients with lower platelet counts (below the median). A p-value <0.05 was considered statistically significant. For MPV, we further performed Cox hazards regression analysis (adjusted for age, sex, FVC, and DLCO) using IBM SPSS Statistics software.

First, we compared xCell enrichment scores for megakaryocytes and platelets between IPF lungs and control lungs. In two independent datasets, GSE47460_GPL6480 and

We next compared the scores for megakaryocyte-erythroid progenitors (MEP) between IPF lungs and control lungs. In mice, the lung has been shown to serve as a reservoir for megakaryocytes and other upstream progenitors (e.g., MEPs, hematopoietic stem cells [HSCs] ) (1) , although the presence of these progenitors in human lungs has not yet been shown.

The scores for MEP were higher in IPF lungs than in controls in the larger dataset, GSE47460_GPL14550, and a similar trend was observed in the smaller dataset, GSE47460_GPL6480 ( Figure 2A ).

We also compared the scores for erythrocytes (downstream of MEP) between IPF lungs and control lungs. In contrast to the scores for MEP, the scores for erythrocytes were lower in IPF lungs than controls in both datasets ( Figure 2B ), as seen in the scores for megakaryocytes ( Figure 1A ). These results suggest that there may be defects in differentiation/transition from MEP to megakaryocytes or erythroid progenitors/erythrocytes in IPF lungs.

We further compared the scores for hematopoietic progenitors upstream of MEP between IPF lungs and control lungs, keeping in mind that the presence of hematopoietic progenitors has been shown in mouse lungs but not yet in human lungs. Interestingly, the scores for HSC were lower, and the scores for common myeloid progenitors (CMP) were higher, in IPF lungs than in control lungs (Supplemental Figure 1 , Figure 2C ). This result raises a possibility that hematopoiesis may be deregulated in IPF lungs (if hematopoiesis truly exists in human lungs, as seen in mouse lungs).

Lower megakaryocyte scores are associated with more advanced stage, lower FVC, and lower microvascular endothelial scores in IPF

We sought to determine factors associated with low megakaryocyte scores in IPF lungs. We hypothesized that lower megakaryocyte scores might be associated with more advanced stage, poorer lung function, and more pulmonary vascular remodeling.

We analyzed the dataset GSE24206, which contains "early" IPF lungs (surgical biopsies) and

"advanced" IPF lungs (explants). Megakaryocyte scores were significantly lower in advanced IPF than in early IPF ( Figure 3A ). We also analyzed datasets that sampled fibrotic areas and non-fibrotic areas from the same individuals in IPF (GSE99621 [three patients]) or combined pulmonary fibrosis with emphysema (CPFE) (GSE38934 [three patients]). In IPF, megakaryocyte scores appeared lower in scarred areas than in normal-appearing areas ( Figure 3B ). In CPFE, megakaryocyte scores appeared lower in fibrotic lesions than in emphysematous lesions ( Figure   3C ). These results are in line with the finding that megakaryocyte scores are lower in advanced IPF than in early IPF.

In the dataset GSE47460_GPL14550, megakaryocyte scores were significantly correlated with All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273424 doi: medRxiv preprint force vital capacity (FVC) in IPF, although the correlation was weak (Pearson r = 0.2510, p=0.0059) ( Figure 4A ). There was no significant correlation between megakaryocyte scores and diffusing capacity for carbon monoxide (DLCO) (Spearman r = 0.1872, p=0.0502) ( Figure 4B ).

In the dataset GSE47460_GPL14550, megakaryocyte scores were significantly correlated with microvascular endothelial cell scores in IPF lungs (Pearson r = 0.5337, p<0.0001) ( Figure 5A , left).

The correlation appeared slightly higher when patients with NSIP and HP were also included in the analysis (r = 0.5664, p<0.0001) ( Figure 5A , right). In the dataset GSE24988, for patients with pulmonary fibrosis (who mostly had usual interstitial pneumonia [UIP]), there was a trend toward a lower megakaryocyte score in patients with mean pulmonary artery pressure (mPAP) >20 mmHg than in patients with mPAP ≤ 20mmHg (p=0.0577) ( Figure 5B ). These results suggest that megakaryocyte scores may be inversely correlated with pulmonary vascular remodeling.

IPF BAL cell transcriptome is less enriched with platelet gene signature than that of healthy controls, and lower platelet scores are associated with worse lung transplant-free survival In the dataset GSE70867, IPF BAL cells had significantly lower platelet scores than control BAL cells ( Figure 6A ). We also investigated whether platelet gene signatures in BAL cells predict survival of IPF patients in this dataset, where information on lung transplant-free survival is available. Patients with lower platelet scores (below the median) had significantly worse lung transplant-free survival rates than patients with higher scores (above the median) (p<0.0001) ( Figure 6B ). These results suggest that platelet biogenesis may be decreased in IPF lungs and that platelet gene signatures in BAL cells may be a novel biomarker to predict lung transplant-free survival in IPF.

We investigated whether megakaryocyte/platelet gene signature in peripheral whole blood transcriptome is altered in IPF compared to healthy controls in two independent datasets (GSE33566 and GSE93606). We chose to investigate the transcriptome of peripheral whole blood rather than peripheral blood mononuclear cells (PBMCs) because we suspected that peripheral whole blood would be more enriched with megakaryocytes and platelets than PBMC. In both datasets, whole blood transcriptome of IPF patients had significantly higher megakaryocyte scores than whole blood transcriptome of age-and sex-matched healthy controls. In other words, the IPF blood transcriptome was significantly more enriched with megakaryocyte gene signature than control blood transcriptomes, in contrast to the lung transcriptome ( Figure 7A ). There was no significant difference in platelet enrichment scores between IPF and controls, although there was a trend toward higher platelet scores in IPF compared to controls ( Figure 7B ). There was weak All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273424 doi: medRxiv preprint but significant negative correlation between megakaryocyte/platelet scores and FVC in the dataset GSE93606. Such correlation was not observed in the dataset GSE33566 (Supplemental Figure 2 ).

Higher megakaryocyte scores in blood transcriptome are associated with worse disease

In the dataset GSE93606, IPF patients with higher megakaryocyte scores had worse disease progression-free survival than IPF patients with lower megakaryocyte scores (p=0.0096) ( Figure   8A ). There was also a trend for worse disease progression-free survival in IPF patients with higher platelet scores compared to IPF patients with lower platelet scores (p=0.1436) ( Figure 8B ). This suggests that a megakaryocyte signature in peripheral whole blood may be a novel biomarker that can predict disease progression in IPF.

We sought to determine whether mean platelet volume (MPV) and platelet counts in peripheral whole blood, two platelet parameters routinely measured in clinical practice (as a part of complete blood count [CBC]), are associated with lung transplant-free survival in IPF. We hypothesized that higher MPV may be associated with worse survival in IPF, given that an increase in blood megakaryocytes or immature platelets might be associated with higher MPV and that higher megakaryocyte scores in blood were associated with worse outcome. We also hypothesized that higher platelet counts may be associated with worse survival (higher mortality) in IPF, given that there was a trend toward worse disease progression-free survival in patients with higher platelet scores in the peripheral whole blood transcriptome.

In our IPF cohort (Table 2) , there was a trend toward worse survival in patients with higher MPV (above the median [9.9 femtoliters]) compared to patients with lower MPV (below the median) (p=0.0940) ( Figure 9A ). On the other hand, higher platelet counts (above the median [227,000 per microliter]) were not significantly associated with lower lung transplant-free survival (p=0.3408) ( Figure 9B ). Of note, univariate analysis with Cox proportional hazards regression model (Table 3) revealed that higher MPV (but not higher platelet counts) was significantly associated with worse lung transplant-free survival (p=0.042). More importantly, multivariate analysis (Table 3) revealed that higher MPV (but not higher platelet counts) was significantly associated with worse lung transplant-free survival, independent of age, sex, FVC, and DLCO (p=0.031) (Multivariate analysis 1, 2). Furthermore, higher MPV (but not higher platelet counts) was significantly associated with worse lung transplant-free survival, independent of age, sex, FVC, DLCO, and platelet counts (p=0.012) (Multivariate analysis 3). These results suggest that MPV in peripheral whole blood may be a simple yet novel biomarker to predict important clinical outcomes such as lung transplant-free survival in IPF. Our overall results are summarized in Table 4 .

Although the presence of megakaryocytes has been reported in human lungs, the characteristics and role of lung megakaryocytes in IPF are not well understood. We tested our hypothesis that megakaryocyte/platelet gene signatures are altered in IPF lung, BAL cells, and blood by analyzing publicly available transcriptome datasets. We calculated gene signature enrichment scores using xCell, a novel bioinformatics tool that assesses enrichment of individual cell types based on gene expression profile. Our analyses indicated that megakaryocyte/platelet gene signatures were altered in IPF in a compartment-specific manner. We found that IPF lung transcriptome was less enriched with a megakaryocyte gene signature than controls. Lower megakaryocyte gene signature enrichment (lower megakaryocyte score) was associated with more advanced disease, poorer lung function, and greater pulmonary vascular remodeling. We also found that the IPF BAL cell transcriptome was less enriched with platelet gene signature compared to controls, and that lower enrichment (lower platelet score) in BAL cells was associated with lower lung transplant-free survival in IPF. In contrast, IPF blood transcriptome was more enriched with megakaryocyte gene signature than controls, and higher enrichment (higher megakaryocyte score) in blood was associated with decreased disease progression-free survival in IPF.

Furthermore, we found that higher MPV in peripheral blood was associated with worse lung transplant-free survival in our IPF cohort.

The finding that the IPF lung transcriptome is less enriched with megakaryocyte gene signature than controls is intriguing. This seems to contradict a previous report that CD41+ megakaryocyte counts are increased in lung tissue of bleomycin-challenged mice (10), possibly reflecting the fact that the bleomycin-induced pulmonary fibrosis mouse model is not able to fully recapitulate human IPF. Our finding suggests a possibility that that IPF lungs harbor fewer (healthy) megakaryocytes due to their altered megakaryocyte niche (i.e., IPF lungs provide a less optimal niche for megakaryocytes) and that megakaryocytes (especially extravascular/interstitial megakaryocytes) are actually decreased in IPF lungs. So far, published single-cell RNA-seq analyses have failed to identify a cluster of lung megakaryocytes in fibrotic lung tissue (11-15).

This may be because lung megakaryocytes are too rare or fragile to be isolated without any enrichment or a special protocol optimized for megakaryocytes. We expect that methods such as single-cell/nuclei RNA-seq with megakaryocyte enrichment techniques and spatial transcriptomics/proteomics will help us define a megakaryocyte niche in healthy and diseased lungs.

The finding that the IPF BAL cell transcriptome is less enriched with platelet gene signature than controls is also intriguing. This seems to contradict a previous report that higher platelet counts in All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ;  BAL fluid were correlated with worse pulmonary fibrosis in a bleomycin-induced pulmonary fibrosis mouse model (16) , further supporting the distinct differences between this mouse model and human IPF. One could speculate that, in IPF, reduced lung megakaryocytes lead to decreased platelet production in lungs, resulting in less spillover of platelets into alveoli. The finding that lower enrichment (lower platelet score) in BAL cells was associated with worse survival in IPF suggests a possibility that platelet gene signature (and/or platelet counts) in BAL fluid may serve as a novel biomarker in IPF. Further studies are needed to explore this possibility.

We are also intrigued by the stark contrast in the megakaryocyte gene signature between lung transcriptome and blood transcriptome in IPF (i.e., IPF lungs showed less megakaryocyte gene signature enrichment than control lungs, whereas IPF blood showed more megakaryocyte gene signature enrichment than control blood). One possibility is that decreased megakaryocyte/platelet biogenesis in IPF lungs induces megakaryocyte/platelet biogenesis in bone marrow. For example, bone marrow may be producing more megakaryocytes and/or releasing more megakaryocytes into the circulation in response to factors released by fibrotic lungs (e.g., CXCL12 (10)) ( Figure 10 ). The second possibility is that megakaryocytes cannot stay in the altered niche within IPF lungs and therefore escape into the circulation. The third possibility is that fibrotic lungs are "educating" circulating platelets and modifying their transcriptome, as shown in previous works on "tumor-educated platelets" (17) . These possibilities could be addressed by further investigations of megakaryocytes/platelets in the circulation and/or bone marrow in IPF patients. For example, transcriptome analysis of those cells is expected to determine whether megakaryocytes and/or immature platelets are increased in IPF and whether platelets in IPF have a distinct gene expression profile.

The findings that the blood transcriptome is more enriched with a megakaryocyte gene signature, and that higher MPV in peripheral blood is associated with worse survival, are novel. A previous study reported that patients with IPF exhibit higher MPV values and lower platelet counts compared to healthy controls (18) . Other studies reported increased platelet reactivity/activation in IPF (19, 20) . However, none of these studies have investigated the association between platelet parameters and important clinical outcomes such as survival. A recent study reported that changes in neutrophil:lymphocyte ratio (NLR) and lymphocyte:platelet ratio (LPR) over 12 months are associated with clinical outcome in IPF (20). However, the authors did not report an association between MPV and clinical outcome. Our finding that higher MPV is associated with worse clinical outcomes needs to be validated in another IPF cohort. A recent study with a small IPF cohort reported (in a preprint) that higher platelet counts are associated with worse survival (21) , but we did not find such an association in our IPF cohort. Their finding should be validated in larger cohorts. Four recent studies with large IPF cohorts reported that higher monocyte counts are associated with worse survival (22-25), but we failed to replicate their finding, probably All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273424 doi: medRxiv preprint because our IPF cohort is much smaller than their cohorts. It remains to be seen whether MPV (or platelet counts) serve as a useful IPF prognostic factor alone and/or in combination with other complete blood count (CBC) parameters such as NLR and monocyte counts.

There are several limitations to our study.

One of the major limitations is that in silico prediction/estimation of gene signature enrichment for various types of cells in tissues is still far from perfect and is especially difficult in rare types of cells. It remains to be seen whether other in silico methods or algorithms outperform xCell, which integrates the advantages of gene enrichment with deconvolution approaches. xCell has been shown to outperform CIBERSORT, a major deconvolution-based method (26), but has not been compared with immunoStates, another deconvolution-based method which has been shown to outperform CIBERSORT (27). At any rate, no in silico algorithm is expected to be perfect in predicting cell composition/enrichment in tissue. Discoveries made using digital dissection methods must be rigorously validated using other technologies (e.g., enrichment for megakaryocytes followed by single-cell/nuclei RNA-seq; spatial transcriptomics/proteomics).

Another limitation is that a megakaryocyte gene signature derived from bone marrow megakaryocytes is unlikely to be fully applicable to lung megakaryocytes, because lung megakaryocytes are transcriptionally (and phenotypically) distinct from bone marrow megakaryocytes. For example, lung megakaryocytes have higher expression of MHC class II and other molecules related to antigen presentation compared to bone marrow megakaryocytes (1-3).

It remains unclear whether megakaryocytes and/or platelets contribute to the pathogenesis of IPF.

Whether the observed decrease in megakaryocyte gene signature in IPF lung and increase in a megakaryocyte signature in IPF blood is the consequence or the cause of pulmonary fibrosis is currently unknown. A previous study with a bleomycin-induced pulmonary fibrosis mouse model suggested that megakaryocytes migrate to injured lung tissue partially through the CXCL12/CXCR4 axis and contribute to fibrogenesis by promoting the proliferation and trans-differentiation of fibroblasts through direct contact and TGF-β1 signaling (10). However, a more recent study reported that megakaryocyte/platelet-specific TGF-β1 conditional knockout mice (PF4-Cre, TGF-β1 floxed mice) were not protected against bleomycin-induced pulmonary fibrosis (21) . We cannot exclude the possibility that megakaryocyte/platelet-derived molecules other than TGF-β1 (e.g., PDGF, IGF-1, polyphosphate (28)) contribute to pulmonary fibrosis.

Further mechanistic studies are needed to determine whether megakaryocytes and/or platelets contribute to the pathogenesis of pulmonary fibrosis.

It also remains unclear whether the human lung is a reservoir of megakaryocyte progenitors and a source of platelet biogenesis, as observed in mouse lungs. Our study suggests that gene All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ;  signatures of megakaryocyte progenitors are present in the human lung transcriptome, but this does not necessarily mean that those cells are actually present in human lungs. Further studies are needed to address this question.

In conclusion, in IPF, megakaryocyte/platelet gene signatures in lung, BAL cells, and blood are altered and may have prognostic value. Moreover, MPV, a platelet parameter routinely measured in clinical practice, may also have prognostic value. Further studies are needed to elucidate megakaryocyte/platelet biogenesis and to validate prognostic utility of megakaryocyte/platelet gene signatures as well as MPV in IPF.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. 

(A) Megakaryocyte scores were significantly lower in "advanced" IPF (explants) than in "early" IPF All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273424 doi: medRxiv preprint (surgical biopsies) in the dataset GSE24206.

(B) In IPF, megakaryocyte scores appeared lower in scarred areas than in normal-appearing areas in the dataset GSE99621, which sampled both fibrotic and non-fibrotic areas from the three IPF patients.

(C) In CPFE, megakaryocyte scores appeared lower in fibrotic lesions than in emphysematous lesions in the dataset GSE38934, which sampled both fibrotic and non-fibrotic areas from three patients. (B) There is a trend toward a lower megakaryocyte score in patients with mean pulmonary artery pressure (mPAP) >20 mmHg than in patients with mPAP ≤ 20mmHg (p=0.0577) in dataset GSE24988, which included patients with pulmonary fibrosis (who mostly had UIP). IPF BAL cells had significantly lower platelet enrichment scores than control BAL cells.

(B) In the dataset GSE70867 (overall cohort = Freiburg + Siena + Leuven), lung transplant-free survival was compared between IPF patients with high platelet scores (i.e., higher than median) and low platelet scores (i.e., lower than median). Patients with lower platelet scores had significantly worse lung transplant-free survival than patients with higher platelet scores (log-rank All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273424 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Peripheral whole blood GSE33566 GSE93606 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ; Table 2 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ; Multivariate analysis revealed that higher MPV (but not higher platelet counts) was significantly associated with worse lung transplant-free survival, independent of age, sex, FVC, and DLCO All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273424 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.04.04.22273424 doi: medRxiv preprint

The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors

Lung megakaryocytes are immune modulatory cells

Lung megakaryocytes display distinct transcriptional and phenotypic properties

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. macrophages in idiopathic pulmonary fibrosis

Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers

A novel murine model of pulmonary fibrosis: the role of platelets in chronic changes induced by bleomycin

Tumor-educated platelets

Mean Platelet Volume as a Surrogate Marker for Platelet Activation in Patients With Idiopathic Pulmonary Fibrosis

Increased Platelet Reactivity in Idiopathic Pulmonary Fibrosis Is Mediated by a Plasma Factor

Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study

Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis